Pharmaxis Receives Maximum Extension of Term to Major European Patent
Release Date: 27/09/2012 12:00am
Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has received notification from the German Patent Office that the European Patent for both Aridol® and Bronchitol® has been extended by five years.
The extension to the patent, through the granting of a Supplementary Protection Certificate (SPC) is for the maximum allowable period of 5 years which will see the Aridol and Bronchitol patent extended from 24th February 2015 to 23rd February 2020.
Categories: News and Media